Treatment of essential thrombocythemia with anagrelide

Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pediatrics 1995-09, Vol.127 (3), p.495-498
Main Authors: Chintagumpala, Murali M., Kennedy, Laura L., Steuber, C.Philip
Format: Article
Language:English
Subjects:
Adolescent
Biological and medical sciences
Blood Cell Count - drug effects
Blood. Blood coagulation. Reticuloendothelial system
Bone Marrow Examination
Child
Drug Evaluation
Female
Humans
Male
Medical sciences
Pharmacology. Drug treatments
Platelet Aggregation - drug effects
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Quinazolines - adverse effects
Quinazolines - therapeutic use
Thrombocythemia, Essential - blood
Thrombocythemia, Essential - drug therapy
Thrombocythemia, Essential - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET. (J P EDIATR 1995; 127:495-8)
ISSN:0022-3476
1097-6833
DOI:10.1016/S0022-3476(95)70090-0